Benzinga | May 7, 2021 10:42AM EDT

UBS Upgrades Ionis Pharmaceuticals to Neutral, Raises Price Target to $37.5

UBS analyst Esther Rajavelu upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Sell to Neutral and raises the price target from $33 to $37.5.